Well, the Multiple Sclerosis market is $19-22 billion. If all comes to fruition, and this drug has great results for the therapy of MS, those revenues of $3-6 billion are very possible. It would be the best therapy for MS.
After speaking to Silvestre, he has been using the therapy for decades and allows him to be much more independent and functional.
Investors and the market will determine the value of this company when all is revealed but most biotechs in trials sit around a $400-1,000,000,000 valuation because of the value of the IP if it goes to market. Not saying that is what happens here in terms of valuations but what I can say is that the pps will move north haha.
Market Data 
Markets 
AI
